Quantity of eligible sufferers: CDEC reviewed the uncertainty in the quantity of people with moderately significant to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some sufferers who're categorized as getting mild or average illness might have a serious bleeding ph